A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
← catalyst calendarNCT06858813 · readout ≤ 1,503 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
232estimated
Sites
22
Countries
China, Israel, Japan +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-14 | actual | When the study began enrolling |
| Primary completion | Sep 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hepatocellular Cancer
- Squamous-Cell Non-Small Cell Lung Cancer
Interventions
- Drug: Lenvatinib
- Drug: ABBV-324
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Adverse Events (AE)s
measured Up to Approximately 4 Years
Number of Participants with Change in Vital Signs
measured Up to Approximately 4 Years
Number of Participants with Change in Electrocardiogram (ECG)
measured Up to Approximately 4 Years
Number of Participants with Change in Clinical Laboratory Tests
measured Up to Approximately 4 Years
Objective Response Rate (ORR)
measured Up to Approximately 4 Years
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed